Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of mRNA-1073 (COVID-19 and Influenza Vaccine) in Healthy Adults
NCT05375838Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- May 2022
- Primary completion
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of mRNA-1073 in coronavirus disease 2019 (COVID-19) and influenza, sponsored by Moderna Inc. Primary endpoints: Number of Participants With Solicited Local and Systemic Adverse Reactions, Number of Participants With Unsolicited Adverse Events and 1 more. Started May 2022; status: completed.
02
Drugs
mRNA-1073
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT05375838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05375838.